Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women  by Auquer, F. et al.
CONCISE COMMUNICATION
Single-dose ciproﬂoxacin versus 3days of norﬂoxacin in uncomplicated
urinary tract infections in women
F.Auquer1, F. Cordo´n1, E. Gorina2, J. C. Caballero3, C. Adalid1, J. Batlle4 and theUrinary Tract Infection Study
Group
1Subdivisio´ d’Atencio´ Prima`ria, Institut Catala` de la Salut, Unitat Docent de Medicina de Famı´lia i
Comunita`ria, c/Santa Clara, 33–35 Girona 17001, 2Medical Department, Q.F. Bayer S.A. Barcelona,
3Garraf Primary Rural Health Area, Barcelona, 4Microbiology Laboratory, ‘Josep Trueta’ Hospital,
Girona, Spain
Tel: þ34 972 20 00 04 Fax: þ34 972 20 39 18 E-mail: p416UFCg@pstaclara.scs.es
A double-blind, randomized controlled study to evaluate the efﬁcacy and safety of a
single dose of 500mg of ciproﬂoxacin versus 3 days 400mg twice-daily of norﬂoxacin in
uncomplicated urinary tract infection in women was designed. Patients underwent four
visits: baseline, and at 3, 7 and 28 days. The main efﬁcacy variables were clinical and
microbiological outcome at day 7. Analyses on both valid patients and intention-to-treat
populations were performed. Two hundred and twenty-six patients (114 receiving
ciproﬂoxacin and 112 receiving norﬂoxacin) were considered valid for efﬁcacy evalua-
tion. Bacteriologic cure was 91.2% in the ciproﬂoxacin group and 91.9% in the norﬂoxacin
group. Clinical resolutionwas 91.2 and 93.8%, respectively. Both treatments were equally
efﬁcacious (P¼ 0.016).
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INTRODUCTION
Twenty per cent of women will experience urinary
infections during their lifetime. Although a num-
ber of single-dose antibacterial treatment studies
[1–5] have shown efﬁcacy in this indication, this
approach is seldom used in primary healthcare, as
it is perceived as a cause of relapse [4,6]. Single-dose
treatments could have clear advantages over longer
ones, including improved compliance, lower cost,
fewer adverse effects and less probability of alter-
ing the normal ﬂora and, thus, of inducing drug
resistance [7]. Ciproﬂoxacin, due to its broad anti-
bacterial spectrum and kinetic proﬁle, with sus-
tained urinary concentrations for over 24 h [8], is
ideal for use in single-dose administration [5,9,10].
A multicenter, double-blind, double-dummy, ran-
domized, controlled clinical trial was performed,
comparing single-dose ciproﬂoxacin (500mg)with
3days of norﬂoxacin (400mg) every 12 hours in
uncomplicated urinary tract infections in women.
PATIENTS AND METHODS
Study population
Women aged 18–65 years attending primary care
centers with symptoms of uncomplicated lower
urinary tract infection (UTI), and positive dipstick
(Multistix 10 SG; Ames Division Bayer Diagnos-
tics, Slough, UK) and urine culture, were enrolled
in the study, being randomly assigned to one of
the study treatments. The exclusion criteria were:
pregnancy or lactation, symptoms of UTI lasting
for more than 7 days, recurrent UTI in the last
year, allergy to quinolones, weight under 45 kg,
background of abnormalities of the urinary
tract, renal lithiasis, urinary catheters, renal or
hepatic failure, suspicion of upper UTI, ongoing
treatment with medications that could interfere
with quinolones, having received antibiotic treat-
ment in the 48 h prior to inclusion, and having
participated in a clinical trial in the previous
30 days.
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A double-blind, double-dummy technique was
used to mask the different number of tablets of
each treatment. Informed consent was obtained
before initiating any study tests.
Urine collection and processing
Mid-micturition urine samples were obtained
using the clean-catch technique. Samples were
analyzed by dipstick and immediately refrigerated
(between 2 8C and 4 8C) for amaximumduration of
48 h—in most cases, less than 24 h—before being
cultured in one of two centralized microbiology
laboratories.
Bacteriologic techniques
Urine samples were cultivated on blood agar,
CLED agar and MacConkey agar. Antibiograms,
MIC90s and inhibitory zones were measured for
both treatments. Bacteriuria was considered sig-
niﬁcant if 105CFU/mL of Gram-negative or
104CFU/mL of Gram-positive organisms were
found.
Visit schedule
Patients were assessed at baseline and at 3, 7 and
28 days after treatment. The day 3 control included
assessment of treatment compliance, exclusion of
clinical symptomatology of upper UTI, evaluation
of subjective clinical response, and a second dip-
stick analysis. On day 7, clinical evaluation and
urine dipstick analysis and culture for microbio-
logical assessment were performed. On day 28,
clinical follow-up and microbiological assessment
were carried out. Any adverse event was noted
and investigated at each study visit.
Sample size
The sample size was calculated at 160 patients per
treatment arm, including a 30% drop-out rate,
allowing equivalence between treatments to be
demonstrated at a level of 80% power.
Definitions of clinical and microbiological
success
A patient was considered clinically cured (resolu-
tion) signs and symptoms of infection disappeared
completely.
Bacterial eradication was considered successful
when <105CFU/mL of Gram-negative bacteria or
<104CFU/mL of Gram-positive bacteria were iso-
lated in the culture at day 7.
Data analysis
Homogeneity of baseline data and patient char-
acteristics in the two treatment groups was ana-
lyzed by ANOVA for the continuous variables and by
the w2-test for the categorical variables. For the prin-
cipal analysis, estimates of the proportion of suc-
cess in each of the two treatment groups were
compared in a unilateral hypothesis test, based
on the formula [11]: Z¼ (PnPc 0.10)/SE, with
SE¼ [Pn (1Pn)/NnþPc (1Pc)/Nc]1/2, where
Pn and Pc are the proportions of successes in each
treatment group, and Nn and Nc are the sample
sizes. Efﬁcacy was analyzed both for the patients
considered valid, meeting all protocol require-
ments, and for the intention-to-treat population.
All patients receiving at least one dose of either
study medication were included in the safety
analysis.
This trial was performed in accordance with
GCP guidelines and with the Declaration of
Helsinki. Informed consent was obtained from
all patients prior to their participation. This trial
was also approved by each center’s Ethical Com-
mittee and by the Spanish Ministry of Health.
RESULTS
Three hundred and twenty-ﬁve patients were ran-
domized: 164 received ciproﬂoxacin, and 161 nor-
ﬂoxacin. Twelve cases were excluded because they
did not attend the subsequent control visits. Of the
remainder, 87 were considered invalid: in 71, there
was no bacterial growth in the initial culture; in
three, the cultures were contaminated; eight cases
did not meet other diagnostic criteria; four cases
did not complywith the therapeutic schedule; and,
in one case, the symptoms had been present for
more than 7days. Thus, 226 patients were consid-
ered valid for themain efﬁcacy analysis (114 receiv-
ing ciproﬂoxacin and 112 receiving norﬂoxacin).
The most frequent microorganisms isolated in
the initial culture were Escherichia coli in 153
patients (65.7%), Proteus mirabilis in 32 (13.7%),
Enterococcus faecalis in 10 (4.3%), Proteus vulgaris
in seven (3.0%), Staphylococcus saprophyticus in
seven (3.0%), Staphylococcus epidermidis in six
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(2.6%), and various other bacteria in the remaining
18 (7.7%).
Tests for homogeneity of the baseline variables
between the two treatment groups revealed no
statistically signiﬁcant differences in terms of
symptoms and signs or in the urine culture anal-
ysis.
The clinical follow-up on day 3 revealed that
74.6% of the patients receiving ciproﬂoxacin and
70.5% receiving norﬂoxacin were already asymp-
tomatic; the remaining patients showed clinical
improvement, and none was considered to be a
clinical failure. At day 7, there was a similar dis-
tribution of the clinical response in both groups;
clinical resolution was found in 104 of the 114
(91.2%) cases assigned to ciproﬂoxacin, and in
105 of the 112 (93.8%) assigned to norﬂoxacin
(Figure 1). Microbiological resolution was found
in 104 cases (91.2%) in the ciproﬂoxacin group and
in 103 (92.0%) in the norﬂoxacin group. No patient
was withdrawn due to in vitro resistance to nor-
ﬂoxacin or ciproﬂoxacin.
The equivalence test resulted in a P-value of
0.01632, rejecting the null hypothesis in favor of
the alternative hypothesis of at least equivalence of
the two treatments. As contemplated in the study
design, the analysis was repeated using alternative
tests based on the normal approach with and
without correction for continuity. All tests yielded
signiﬁcant results in favor of the hypothesis of at
least equivalence. In particular, the Dunnet–Gent
w2-test with correction for continuity gave a P-
value of 0.0062. The point estimate establishing
the difference in the proportion of successes
between the two treatments (norﬂoxacin minus
ciproﬂoxacin) was 93.75 91.23¼ 2.52%, with a
95% conﬁdence interval of 4.33–9.37, lower than
the 10% value deﬁned as the limit of equivalence in
this study. Furthermore, analysis on the intention-
to-treat population (n¼ 313) gave the same results
as found in the valid patient subpopulation; 91.5%
for norﬂoxacin and 89.38% for ciproﬂoxacin, with
a P-value of 0.00536.
No differences in efﬁcacy were found when
analyzing the results stratiﬁed by the two most
frequently isolated microorganisms, E. coli and P.
mirabilis.
At day 28, 97 of the 104 patients in the cipro-
ﬂoxacin group remained asymptomatic. Of the
seven remaining cases, six had recurrence of
Figure 1 Clinical and microbiological responses at day 7.
Table 1 Safety and tolerability: adverse events
Patients with
adverse events
n (%)
Intensity
(%)
Relation to
study druga
Type of
adverse event
Ciprofloxacin 21 (12.7) Mild 76% 17 Gastrointestinal 14/17
Moderate 19% Other 3/17b
Severe 5%
Norfloxacin 18 (11.3) Mild 65% 13 Gastrointestinal 8/13
Moderate 35% CNS 3/13
Other 2/13c
aNo. of adverse events with possible or probable relation to study drug.
CNS, central nervous system.
bVulvar itching (possible); Pyelonephritis (possible); Candidiasis (possible).
cPyelonephritis (possible); Candidiasis (possible).
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urinary symptoms with positive culture and one
was lost to follow-up. In the norﬂoxacin group,
98 of the 103 patients remained asymptomatic;
four had symptoms compatible with UTI and
positive culture, and one patient was lost to
follow-up.
All patients receiving at least one dose of any
study drug (n¼ 324) entered the safety assessment
(159 for norﬂoxacin and 165 for ciproﬂoxacin). The
results are displayed in Table 1.
DISCUSSION
The results of this study show that both treatments
are effective in the treatment of uncomplicated
UTIs in women. The same conclusion may be
drawn from analysis of the intention-to-treat
population. The cure rates for ciproﬂoxacin and
norﬂoxacin at day 7 (91.2 and 92%, respectively)
were similar to those found in other studies
[12,13]. No in vitro resistance to the test drugs
was found in the initial cultures, in those cases
in which cure was not achieved, or in subsequent
re-infections or relapses. This has also been ob-
served in other studies of single-dose treatment
with ﬂuoroquinolones [12,13]. This ﬁnding can be
explained by the study exclusion criteria, and thus,
by the relatively healthy background of the en-
rolled patients. Epidemiological studies performed
in the same geographic areas which included a
wider range of patient conditions revealed a low
percentage of microbiological resistance to ﬂuoro-
quinolones [14,15].
It is worth noting that this study has been con-
ducted in line with regular primary care practice
for a patient with clinical symptoms and a dipstick
urine test compatible with an uncomplicated UTI;
empirical treatment would normally be given
without awaiting microbiological conﬁrmation.
Such patients would usually be treated empirically
with norﬂoxacin for 3 days in accordance with
the understanding that single-dose treatments
increase the number of relapses due to a failure
to eliminate the vaginal reservoir of coliforms
[6,16]. In this study, no signiﬁcant differences were
found in the relapse rates after 4weeks in the two
groups being compared, challenging the above
understanding.
Some authors suggest that symptoms of uncom-
plicated UTI associated with 103CFU/mL of
uropathogens on urine culture establishes the
diagnosis of uncomplicated UTI [17]. However,
in this trial, the requirements were increased,
particularly regarding the number of colonies in
the cultures, in order to avoid the inclusion of
patients without clear evidence of infection ac-
cording to more stringent, widely accepted stan-
dards. This gave rise to a subgroup of patients with
probable lower UTI but in whom, for whatever
reason, the growth of microorganisms in the cul-
tures did not reach the accepted limits. These
patients were included, however, in the inten-
tion-to-treat analysis, giving the same conclusions.
In contrast to other studies, we have not found
differences in the efﬁcacy of both study regimens
for the subgroups of microorganisms with at least
10 isolated cases [18].
As previously described, both treatments were
generally well tolerated [19,20]. Few adverse
events were drug related, and most were mild.
The most frequent adverse events were gastroin-
testinal, and all resolved.
To summarize, although a literature review [21]
revealed that single-dose treatments appear to be
less effective than longer treatments with regard to
bacterial eradication, the results of this study sug-
gested that a single-dose treatment with ciproﬂox-
acin was equally effective as a 3-day regimen with
norﬂoxacin. Accordingly, we recommend the use
of ciproﬂoxacin in single-dose treatment in
uncomplicated UTI in women, due to ease of
administration, low incidence of adverse affects,
and lower cost than a 3-day treatment regimen.
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